BC1618

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

BC1618 是一种口服活性 Fbxo48 抑制化合物，可刺激 Ampk 依赖性信号传导。

BC1618 is an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling. It promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity.

Western Blot Analysis Cell Line:BEAS-2B cells.Concentration:0-2 μM.Incubation Time:16 h.Result:Induced pAmpkα and pACC protein levels dose-dependently.

Animal Model:C57BL/6 mice.Dosage:2 or 10 mg/kg (challenged with LPS (3 mg/kg) for an additional 18 h).Administration:IP, once.Result:Reduced lung inflammation in endotoxin treated mice.Animal Model:C57BL/6 mice.Dosage:15 and 30 mg/kg/d.Administration:Drinking water for 3 months.Result:Exhibited no obvious toxicity.

2-Propanol, 1-[bis(phenylmethyl)amino]-3-[4-(trifluoromethyl)phenoxy]-

Membrane Transporter/Ion Channel

AMPK

AMPK|E1/E2/E3 Enzyme|Fbxo48|Mitophagy

——

——

2222094-18-8

415.45

C24H24F3NO2

>98% (HPLC)

DMSO:100 mg/mL?(240.70 mM;?Need ultrasonic)

OC(COC1=CC=C(C(F)(F)F)C=C1)CN(CC2=CC=CC=C2)CC3=CC=CC=C3

——

(-20℃)

With Ice Pack

≥ 2 years